ICON plc to present at the BofA Securities 2022 Healthcare Conference
Tuesday, May 10, 2022, at 5:20pm PT.
ICON reports first quarter 2022 results
Quarter 1 adjusted revenue of $1.901.8 million representing a year on year increase of 121.6% or 125% on a constant currency basis.
ICON plc to Webcast Analyst Day Meeting
Thursday, March 17, 2022 at 12:30 ET.
ICON Reports Fourth Quarter and Full Year 2021 Results
Record net business wins in the quarter of $2,378 million; a net book to bill of 1.26. Full year net business wins of $6,958 million; a net book to bill of 1.27.
ICON plc to Present at the 2022 Citi Healthcare Conference
Thursday, February 24, 2022 at 11:45 ET.
ICON Issues Financial Guidance for Full Year 2022
Full Year 2022 adjusted earnings per share guidance in the range of $11.55 - $11.95, representing growth of 21 – 23% over Full Year 2021 adjusted earnings per share guidance.
ICON plc to Present at the 40th Annual JP Morgan Healthcare Conference
A world-leading healthcare intelligence and clinical research organisation, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the 40th Annual JP Morgan Healthcare Conference
ICON named best Contract Research Organisation in latest string of awards and recognitions
ICON and its drug and device development work continues to be recognised by peers, employees, and organisations around the globe
ICON Releases Environmental, Social and Governance Report
ICON announced the release of its 2020 Environmental, Social and Governance Report. The report looks to the future of ESG for the new ICON while highlighting advancements made in 2020.
ICON announces the expansion of its Accellacare Site Network
New partnerships increase geographical footprint, supporting more access to patients and strengthening therapeutic capability